Pyridazine compounds as glycogen synthase kinase 3 inhibitors

Details Pyridazine compounds as glycogen synthase kinase 3 inhibitors Pyridazine compounds as glycogen synthase kinase 3 inhibitors

2011-08-09

2011-08-09

Kifle, Bruck (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Heterocyclic carbon compounds containing a hetero ring...

C514S211050, C514S211060, C514S220000, C514S221000, C540S488000, C540S490000, C540S495000, C540S502000

Reexamination Certificate

active

07994160

ABSTRACT:
Disclosed are pyridazine compounds of the formula I which are useful for inhibiting glycogen synthase kinase 3 (GSK-3), methods of making the compounds, compositions containing the compounds, and methods of treatment using the compounds:In formula Iindicates a single bond or a double bond;X is O, S or N—R5;R1, R2are independently selected from the group consisting of H, NH2, NH—C1-C6-alkyl, OH, ═O, (i.e. a carbonyl group), C1-C6-alkoxy, halogen, methyl, C2-C4-alkyl, C3-C4-cycloalkyl, C3-C4-alkenyl, fluorinated C1-C4-alkyl, fluorinated C3-C4-cycloalkyl, fluorinated C3-C4-alkenyl, formyl, C1-C3-alkylcarbonyl, and an aromatic radical Ar,R1and R2together with the carbon atoms, to which they are attached, form a fused, saturated or unsaturated 5-, 6- or 7-membered C-bound carbocyclic or heterocyclic ring comprising 1 heteroatom, selected from nitrogen, oxygen and sulfur as ring member and 0, 1 or 2 further heteroatoms, independently selected from O, S and N, as ring members, wherein the fused ring is unsubstituted or may carry 1, 2 or 3 substituents selected, independently of each other, from the group of radicals R4as defined below;R3is hydrogen OH, halogen, CN, nitro, C1-C6-alkyl, fluorinated C1-C6-alkyl, C1-C6-hydroxyalkyl, C1-C6-alkoxy-C1-C6-alkyl, C2-C6-alkenyl, fluorinated C2-C6-alkenyl, C2-C6-alkynyl, C3-C7-cycloalkyl, fluorinated C3-C7-cycloalkyl, C1-C6-alkoxy, C1-C6-hydroxyalkoxy, C1-C6-alkoxy-C1-C6-alkoxy, fluorinated C1-C6-alkoxy, C1-C6-alkylthio, fluorinated C1-C6-alkylthio, C1-C6-alkylsulfinyl, fluorinated C1-C6-alkylsulfinyl, C1-C6-alkylsulfonyl, fluorinated C1-C6-alkylsulfonyl, C1-C6-alkylcarbonyl, fluorinated C1-C6-alkylcarbonyl, C1-C6-alkylcarbonylamino, fluorinated C1-C6-alkylcarbonylamino, carboxy, C1-C6-alkyloxycarbonyl, fluorinated C1-C6-alkoxycarbonyl, NRaRb, C(O)—NReRf, NH—C(O)—NReRf, NRaRb—C1-C6-alkylene, O—NRaRb, etc.and wherein R4and R5are as defined in the specification and the claims.

REFERENCES:
patent: 7232814 (2007-06-01), Meijer et al.
patent: WO 01/60374 (2001-08-01), None
Ott, Ingo et al., “Substituted Pyridazino[3,4-b][1,5]benzoxapin-5(6H)on es as Multidrug-Resistance Modulating Agents” Journal of Medicinal Chemistry, 47(18), 4627-4630 CODEN: JMCMAR; ISSN: 0022-2623, 2004 XP002406965.
Heinisch et al., “Synthesis of Substituted Tri- and Tetracyclic Compounds Bearing a Pyridazine Core and their Biological Evaluation as Anitmycobacterial Agents” Arch. Phar. Pharm. Med. Chem., vol. 333, 2000, pp. 231-240, XP009074716.
Heinisch et al., “Pyridazines. 81. A novel 1,2-diazine containing tricyclic system: synthesis of pyridazinol[3,4-b][1,5]benzodiazepin-5-ones as potential HIV-1 reverse transcriptase inhibitors”, Heterocycles, 45(4), pp. 673-682 CODEN: HTCYAM; ISSN: 0385-5414, 1997, XP001248027.
Heinisch et al., “Synthesis of Pyridazino[3,4-b][1,5]benzodiazepin-5-ones and their Biological Evaluation as Non-nucleoside HIV Reverse Transcriptase Inhibitors” Arch. Pharm. Pharm. Med. Chem., vol. 330, 1997, pp. 29-34, XP009074715.
Barth et al., “Pyridazino[3,4-b][1,5]benzoxazepin-5(6H)-ones: synthesis and biological evaluation” Antiviral Chemistry and Chemotherapy, 7(6), pp. 300-312 CODEN: ACCHEH; ISSN: 0956-3202, 1996, XP009074718.
Tavares et al., “N-Phenyl-4-pyrazolo[1,5-b]pyridazin-3ylpy rimidin-2-amines as Potent and Selective Inhibitors of Glycogen Synthase Kinase 3 with Good Cellular Efficacy” J. Med. Chem., vol. 47, 2004, pp. 4716-4730, XP002406982.

Affiliated with

Also associated with

Rating

Pyridazine compounds as glycogen synthase kinase 3 inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Pyridazine compounds as glycogen synthase kinase 3 inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pyridazine compounds as glycogen synthase kinase 3 inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2768615